DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $359 | -37.5% | 17,381 | -30.2% | 0.00% | -40.0% |
| Q1 2023 | $574 | -99.9% | 24,907 | +6.3% | 0.01% | -44.4% |
| Q3 2022 | $719,000 | -61.9% | 23,434 | -63.5% | 0.01% | -60.9% |
| Q2 2022 | $1,889,000 | +14.9% | 64,187 | +206.3% | 0.02% | +27.8% |
| Q2 2021 | $1,644,000 | +702.0% | 20,959 | +266.2% | 0.02% | +350.0% |
| Q3 2020 | $205,000 | -45.8% | 5,723 | -63.4% | 0.00% | -60.0% |
| Q2 2020 | $378,000 | +147.1% | 15,637 | +56.4% | 0.01% | +100.0% |
| Q3 2019 | $153,000 | -52.2% | 10,000 | -27.4% | 0.01% | -79.2% |
| Q1 2019 | $320,000 | – | 13,770 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $219,569,000 | 28.65% |
| ARCH Venture Management, LLC | 5,168,749 | $152,116,000 | 18.54% |
| Casdin Capital, LLC | 1,500,000 | $44,145,000 | 3.73% |
| Flagship Pioneering Inc. | 2,619,968 | $77,106,000 | 2.90% |
| Yiheng Capital Management, L.P. | 1,014,684 | $29,862,000 | 1.71% |
| SECTORAL ASSET MANAGEMENT INC | 202,100 | $5,948,000 | 1.20% |
| GILDER GAGNON HOWE & CO LLC | 1,956,820 | $57,589,000 | 1.03% |
| Artal Group S.A. | 600,000 | $17,658,000 | 0.94% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $158,024,002 | 0.87% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $283,000 | 0.69% |